Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079246 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,463
- Enrollment target
NCT02079246 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 1,463 participants.
The verdict
NCT02079246, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,463 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
Interventions
- DRUG Idalopirdine 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,463 participants |
| Start Date | 2014-04-07 |
| Est. Completion | 2017-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02079246
The ClinicalTrials.gov registry entry for NCT02079246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,463 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idalopirdine 60 mg is the first listed.
NCT02079246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02079246 about?
NCT02079246 is a clinical study titled "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease". To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
What is the current status of trial NCT02079246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,463 participants. The study started on 2014-04-07. Estimated completion is 2017-07-06.
What interventions are being tested in trial NCT02079246?
The interventions under investigation include: Idalopirdine 60 mg (DRUG).
Who is sponsoring clinical trial NCT02079246?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.